Drugs
Conditions
News and resources
MIMS Supported ResourcesSecukinumab approved by NICE for severe psoriasis
The monoclonal antibody secukinumab (Cosentyx) has been endorsed by NICE for use in patients with severe plaque psoriasis who have not responded to, or have an intolerance or contraindication to, standard systemic therapies
To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content. View our subscription and registration options.